Literature DB >> 23870818

Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.

Marcin Skrzypski1, Rafał Dziadziuszko, Ewa Jassem, Amelia Szymanowska-Narloch, Grażyna Gulida, Robert Rzepko, Wojciech Biernat, Miquel Taron, Małgorzata Jelitto-Górska, Tomasz Marjański, Witold Rzyman, Rafael Rosell, Jacek Jassem.   

Abstract

BACKGROUND: There is increasing evidence that suggests that particular histopathologic types of non-small-cell lung cancer (NSCLC) display distinct molecular characteristics. We analyzed, in lung squamous cell carcinoma (SCC) and adenocarcinoma (AC), the expression of 8 genes that constitute 2 previously reported prognostic expression signatures in NSCLC.
METHODS: Fresh-frozen tumor and normal lung samples were obtained at surgery from 135 patients with stage I-III NSCLC (89 (65.9%) SCC, 46 (34.1%) AC). Expression of CSF1 (colony stimulating factor for macrophages), carbonic anhydrase 9 (CA9), epithelial growth factor receptor (EGFR), dual specificity phosphatase 6 (DUSP6), v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3), monocyte to macrophage differentiation-associated (MMD), lymphocyte-specific protein tyrosine kinase (LCK) and signal transducer and activator of transcription 1 (STAT1) was assessed in SCC, AC, and in normal lung by quantitative reverse transcriptase - polymerase chain reaction (qRT-PCR). Metastasis-free survival was analyzed according to the median value of gene expression in the entire NSCLC cohort and separately in SCC and AC.
RESULTS: Expression of CA9, CSF1, DUSP6, STAT1, and MMD differed between NSCLC and normal lung. EGFR was more abundant in SCC compared with AC, whereas the reverse was true for DUSP6 and ERBB3. A high expression of CSF1 correlated with shorter metastasis-free survival in the entire NSCLC group (P = .016) and in SCC (P = .049) and AC (P = .034) cohorts.
CONCLUSIONS: Several genes considered prognostic in NSCLC showed significantly different expression in SCC and AC, and thus should be analyzed separately in these 2 subtypes for their prognostic significance. CSF1 is similarly expressed in SCC and AC, and portends a poor outcome in the entire group of patients with NSCLC, and in SCC and AC when considered separately.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant chemotherapy; Gene expression; Lung adenocarcinoma; Prognosis; Reverse transcriptase-polymerase chain reaction; Squamous cell lung cancer

Mesh:

Substances:

Year:  2013        PMID: 23870818     DOI: 10.1016/j.cllc.2013.04.010

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  19 in total

1.  Potential Role of TRAIL in Metastasis of Mutant KRAS Expressing Lung Adenocarcinoma.

Authors:  Shyama Pal; Prayag J Amin; K B Sainis; Bhavani S Shankar
Journal:  Cancer Microenviron       Date:  2016-04-23

2.  Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer.

Authors:  Garrett L Jensen; Chad Tang; Kenneth R Hess; Zhongxing Liao; Daniel R Gomez
Journal:  Clin Exp Metastasis       Date:  2017-07-25       Impact factor: 5.150

3.  Computed tomography radiomic features hold prognostic utility for canine lung tumors: An analytical study.

Authors:  Hannah Able; Amber Wolf-Ringwall; Aaron Rendahl; Christopher P Ober; Davis M Seelig; Chris T Wilke; Jessica Lawrence
Journal:  PLoS One       Date:  2021-08-17       Impact factor: 3.240

4.  Radiomics for Classifying Histological Subtypes of Lung Cancer Based on Multiphasic Contrast-Enhanced Computed Tomography.

Authors:  Linning E; Lin Lu; Li Li; Hao Yang; Lawrence H Schwartz; Binsheng Zhao
Journal:  J Comput Assist Tomogr       Date:  2019 Mar/Apr       Impact factor: 1.826

5.  Radiomics-Based Features for Prediction of Histological Subtypes in Central Lung Cancer.

Authors:  Huanhuan Li; Long Gao; He Ma; Dooman Arefan; Jiachuan He; Jiaqi Wang; Hu Liu
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

6.  Prognostic value of microRNA expression in operable non-small cell lung cancer patients.

Authors:  M Skrzypski; P Czapiewski; K Goryca; E Jassem; L Wyrwicz; R Pawłowski; W Rzyman; W Biernat; J Jassem
Journal:  Br J Cancer       Date:  2014-01-21       Impact factor: 7.640

Review 7.  Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling.

Authors:  Amy R Dwyer; Eloise L Greenland; Fiona J Pixley
Journal:  Cancers (Basel)       Date:  2017-06-18       Impact factor: 6.639

8.  Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.

Authors:  David Gyori; Ee Lyn Lim; Francis M Grant; Dominik Spensberger; Rahul Roychoudhuri; Stephen J Shuttleworth; Klaus Okkenhaug; Len R Stephens; Phillip T Hawkins
Journal:  JCI Insight       Date:  2018-06-07

9.  Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.

Authors:  Ander Aramburu; Isabel Zudaire; María J Pajares; Jackeline Agorreta; Alberto Orta; María D Lozano; Alfonso Gúrpide; Javier Gómez-Román; Jose A Martinez-Climent; Jacek Jassem; Marcin Skrzypski; Milind Suraokar; Carmen Behrens; Ignacio I Wistuba; Ruben Pio; Angel Rubio; Luis M Montuenga
Journal:  BMC Genomics       Date:  2015-10-06       Impact factor: 3.969

10.  Cell-surface marker discovery for lung cancer.

Authors:  Allison S Cohen; Farah K Khalil; Eric A Welsh; Matthew B Schabath; Steven A Enkemann; Andrea Davis; Jun-Min Zhou; David C Boulware; Jongphil Kim; Eric B Haura; David L Morse
Journal:  Oncotarget       Date:  2017-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.